Login / Signup

Anti-PD-L1 antibody TQB2450 combined with tyrosine kinase receptor inhibitor AL2846 for immunotherapy-refractory advanced hepatocellular carcinoma and esophageal squamous cell carcinoma: A prospective phase 1b cohort study.

Tao NingDanyang LiTing DengYuxian BaiYe ChenZhiyu WangBin HuYi BaWei Lu
Published in: Cancer (2024)
Combined TQB2450 and AL2846 therapy exhibited a favorable safety profile in immunotherapy-refractory patients with advanced ESCC and HCC.
Keyphrases
  • tyrosine kinase
  • epidermal growth factor receptor
  • stem cells
  • cell therapy
  • binding protein
  • smoking cessation